Jubilant Pharmova Ltd
Jubilant Pharmova Ltd (JUBLPHARMA) last traded at ₹899, a market capitalisation of ₹14,318 crore, on a P/E of 36.9. Over the past 52 weeks the stock has ranged between ₹784 and ₹1,185. Jubilant Pharmova Ltd last reported results for the quarter ended Jun 2026, with sales of ₹2,229 crore and net profit of ₹56 crore. Figures are as of 25 Aug 2026 and are not real time.
Jubilant Pharmova Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Jubilant Pharmova Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,229 cr, up 17.3% from ₹1,901 cr a year earlier. Net profit was ₹56 cr, down 45.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,122 | 2,290 | 2,229 |
| Expenses | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 | 1,833 | 1,951 | 1,981 |
| Operating profit | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 |
| OPM % | 17% | 16% | 18% | 15% | 17% | 14% | 15% | 11% |
| Other income | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 |
| Interest | 61 | 56 | 53 | 49 | 50 | 56 | 56 | 54 |
| Depreciation | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 |
| Profit before tax | 144 | 130 | 206 | 154 | 190 | 93 | 176 | 86 |
| Tax % | 29% | 23% | 27% | 34% | 37% | 40% | 32% | 35% |
| Net profit | 102 | 101 | 151 | 102 | 120 | 56 | 119 | 56 |
| EPS (₹) | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 | 3.51 | 7.50 | 3.55 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Jubilant Pharmova Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 6,099 | 6,130 | 6,282 | 6,703 | 7,234 | 8,280 | 8,608 |
| Operating profit | 1,403 | 1,150 | 779 | 901 | 1,173 | 1,260 | 1,218 |
| OPM % | 23% | 19% | 12% | 13% | 16% | 15% | 14% |
| Net profit | 836 | 413 | -65 | 73 | 836 | 398 | 351 |
| EPS (₹) | 52.47 | 25.98 | -3.83 | 4.84 | 52.69 | 25.02 | 22.11 |
TTM is the trailing twelve months to the most recent quarter.
Jubilant Pharmova Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 6%
- 3 Years
- 10%
- TTM
- 16%
- 10 Years
- 1%
- 5 Years
- -13%
- 3 Years
- 47%
- TTM
- -20%
- 10 Years
- 7%
- 5 Years
- 8%
- 3 Years
- 26%
- 1 Year
- -16%
- 10 Years
- 9%
- 5 Years
- 3%
- 3 Years
- 5%
- Last Year
- 7%
Jubilant Pharmova Ltd shareholding pattern
Promoters held 47.67% at Jun 2026, broadly unchanged since Jun 2025. FIIs 15.87% and DIIs 12.40%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.67% | 50.67% | 50.67% | 47.67% | 47.67% | 47.67% | 47.67% | 47.67% |
| FIIs | 17.94% | 16.96% | 17.23% | 17.40% | 16.56% | 15.96% | 15.90% | 15.87% |
| DIIs | 5.66% | 6.99% | 7.05% | 9.52% | 10.53% | 11.23% | 11.63% | 12.40% |
| Public | 25.17% | 24.82% | 24.48% | 24.83% | 24.60% | 24.57% | 24.25% | 23.50% |
| No. of shareholders | 89,456 | 1,02,442 | 96,526 | 99,673 | 93,336 | 90,133 | 86,347 | 82,703 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Jubilant Pharmova Ltd corporate filings
- USFDA Approval for Line 3, Contract manufacturing facility, Spokane, USACompany Updatehigh impact
Cruxal's analysis: Jubilant Pharmova Limited has secured USFDA approval for commercial batch manufacturing…
Read the full analysis - Scrutinizer''s ReportAGM/EGMlow impact
Cruxal's analysis: Jubilant Pharmova Limited has confirmed the re-appointment of Mr. Priyavrat Bhartia as…
Read the full analysis - Newspaper PublicationsCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova Ltd has released the mandatory newspaper publications as per Regulation…
Read the full analysis - Press Release and presentationCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova has filed an investor presentation dated August 10, 2026, providing…
Read the full analysis - outcome of Board meetingBoard Meetinghigh impact
Cruxal's analysis: Jubilant Pharmova Limited reported consolidated revenue from operations of 2,229 crore…
Read the full analysis - Investors/ Analysts MeetingCompany Updatelow impact
Cruxal's analysis: Jubilant Pharmova has issued an intimation regarding an analyst/investor meeting…
Read the full analysis - Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Un-audited Standalone ....Company Updatelow impact
Cruxal's analysis: Jubilant Pharmova Limited has announced the postponement of its Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Jubilant Pharmova Ltd
Cruxal reads every Jubilant Pharmova Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.